Scholarlink

Background and objective <p>People with multiple sclerosis (PwMS) may be at an increased risk of surgical&#xa0;site infections&#xa0;(SSIs). However, the role of specific MS disease-modifying therapies (DMTs) in modulating this risk remains underexplored.</p> Methods <p>The FDA Adverse Event Reporting System (FAERS) was used to investigate if MS DMTs are associated with disproportionally higher SSI&#xa0;reporting compared to other FAERS medications for individuals of all ages and those over the age of 50.</p> Results <p>We identified 769 reports of SSIs across MS DMTs (352 in PwMS aged 50 or older) and 21 SSI-associated deaths. A pooled analysis of all DMTs revealed increased risks of SSIs (reporting odds ratio [ROR] of 1.95, 95% confidence interval [CI] 1.80–2.12) for all age groups and for those 50 or older (ROR of 2.58, 95% CI 2.27–2.92). For both age groups, ocrelizumab and interferon beta-1a met Evan’s threshold for disproportionally high SSI reporting compared to all other FAERS medications.</p> Conclusion <p>MS DMTs are collectively associated with disproportionately high SSI reporting, especially for PwMS over the age of 50, with ocrelizumab and interferon beta-1a increasing SSI reporting risk in both age groups. These findings reveal a need to take extra precautions when caring for PwMS in a surgical setting, such as engaging wound care teams to minimize SSI risk.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A disproportionality analysis of surgical site infections across multiple sclerosis disease modifying therapies

  • 期刊论文

  • 发表日期：

    2025年2月22日

查看全文
  • Alexandra Balshi,
  • John Dempsey,
  • Nova Manning,
  • Grace Leuenberger,
  • Ursela Baber,
  • Jacob A. Sloane

摘要

Background and objective

People with multiple sclerosis (PwMS) may be at an increased risk of surgical site infections (SSIs). However, the role of specific MS disease-modifying therapies (DMTs) in modulating this risk remains underexplored.

Methods

The FDA Adverse Event Reporting System (FAERS) was used to investigate if MS DMTs are associated with disproportionally higher SSI reporting compared to other FAERS medications for individuals of all ages and those over the age of 50.

Results

We identified 769 reports of SSIs across MS DMTs (352 in PwMS aged 50 or older) and 21 SSI-associated deaths. A pooled analysis of all DMTs revealed increased risks of SSIs (reporting odds ratio [ROR] of 1.95, 95% confidence interval [CI] 1.80–2.12) for all age groups and for those 50 or older (ROR of 2.58, 95% CI 2.27–2.92). For both age groups, ocrelizumab and interferon beta-1a met Evan’s threshold for disproportionally high SSI reporting compared to all other FAERS medications.

Conclusion

MS DMTs are collectively associated with disproportionately high SSI reporting, especially for PwMS over the age of 50, with ocrelizumab and interferon beta-1a increasing SSI reporting risk in both age groups. These findings reveal a need to take extra precautions when caring for PwMS in a surgical setting, such as engaging wound care teams to minimize SSI risk.